Loading...
Market
Story
Eli Lilly Releases Tirzepatide Vials at 50% Discount to Boost Access and Supply
Aug 26, 2024, 03:00 PM
Eli Lilly has announced the release of single-dose vials of its popular weight-loss drug, Zepbound (tirzepatide), in the U.S. The vials are available in 2.5 mg and 5 mg doses, priced at $399 and $549 per month, respectively. This move aims to expand supply and accessibility, particularly for patients who cannot get the cost of the medicine reimbursed through their health insurance plans. The introduction of these vials is expected to ease supply constraints and provide a more affordable option compared to injection pens, which are priced higher.
View original story
Similar markets
2-12 years • 25%
13-24 years • 25%
25-35 years • 25%
36-49 years • 25%
18-34 • 25%
35-49 • 25%
50-64 • 25%
65+ • 25%
2-12 years • 25%
13-24 years • 25%
25-49 years • 25%
Evenly distributed • 25%
2-18 years • 25%
19-29 years • 25%
30-49 years • 25%
All age groups equally • 25%
2-12 years • 25%
13-24 years • 25%
25-34 years • 25%
35-49 years • 25%
Children (6 months to 11 years) • 25%
Adolescents (12 to 17 years) • 25%
Adults (18 to 64 years) • 25%
Seniors (65 years and older) • 25%
18-24 • 25%
25-34 • 25%
35-44 • 25%
45+ • 25%
2-12 years • 25%
13-24 years • 25%
25-49 years • 25%
50+ years • 25%
65-74 • 25%
75-84 • 25%
85 and older • 25%
Immunocompromised individuals • 25%
12-17 years • 25%
18-29 years • 25%
30-49 years • 25%
50+ years • 25%
0-17 years • 25%
18-49 years • 25%
50-64 years • 25%
65+ years • 25%
2-12 years • 25%
13-29 years • 25%
30-49 years • 25%
Equal uptake across all age groups • 25%